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BY-NC-ND license (http://creativecomBackground/Purpose: Decoy receptor 3 (DcR3), a soluble receptor of the tumor necrosis factor
receptor superfamily, is a pleiotropic immunomodulator. The aim of this study was to investi-
gate serum DcR3 levels in atopic and nonatopic asthma patients.
Methods: The serum DcR3 levels of 70 adults with asthma and 20 healthy controls were deter-
mined by enzyme-linked immunosorbent assay (ELISA). The asthma patients were divided into
atopic and nonatopic subgroups, based on the presence or absence of immunoglobulin E (IgE)
specific to allergen. Correlations between serum DcR3 levels and blood total-eosinophil
counts, forced expiratory volume in 1 second (FEV1), FEV1/forced vital capacity (FVC), and
Asthma Control Test (ACT) scores were analyzed.
Results: The mean serum DcR3 level was significantly higher in asthma patients than in healthy
controls (266.1  60.6 pg/mL vs. 63.7  21.9 pg/mL, pZ 0.003), but there was no significant
difference between the mean serum DcR3 level of asthma patients with atopy (37 patients)
and patients without atopy (33 patients; 298.7  111.2 pg/mL vs. 230.6  38.5 pg/mL,
pZ 0.064). However, the serum DcR3 level was positively correlated with the total eosinophilave no conflicts of interest relevant to this article.
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50 M.-H. Chen et al.count (rZ 0.448, pZ 0.012) and inversely correlated with the percentages of predicted FEV1,
FEV1/FVC, and ACT score (r Z 0.409, p Z 0.018; r Z 0.399, p Z 0.021; and r Z 0.505,
p Z 0.003, respectively) in nonatopic asthma patients, but not in atopic patients.
Conclusion: High serum DcR3 levels are associated with disease severity in nonatopic asthma
patients, which suggests that DcR3 is a potential biomarker that can be used to predict the
severity of nonatopic asthma.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Asthma is a chronic lung disease characterized by inter-
mittent chest symptoms such as wheezing, dyspnea, chest
tightness, and cough. Chronic inflammation in asthma re-
sults in airway remodeling such as bronchial smooth muscle
contraction, increased airway wall thickness, and hyper-
secretion of mucus. Asthma was traditionally considered an
allergic disease, and allergen-specific immunoglobulin (Ig) E
antibodies, mast cells, T helper 2 (Th2) cells, and Th2 cy-
tokines contribute to the pathophysiology of atopic
asthma.1,2 However, some patients with asthma do not
appear to be allergic; they experience their first asthma
attack in adulthood without preceding allergic diseases and
without exhibiting allergen-specific IgE. Several risk factors
for nonatopic asthma have been investigated such as a
family history of asthma, genetic background, current or
past dampness, and lower respiratory tract infections.3 It
has been demonstrated that homozygosity for matrix
metalloproteinase-9 variants increases the risk of devel-
oping nonatopic asthma4 and that the interferon-g levels in
allergen-stimulated total peripheral blood mononuclear
cells are higher in nonatopic asthma patients.5 However,
serum markers correlated with disease severity in non-
atopic asthma patients have not been reported.
Decoy receptor 3 (DcR3), a member of the tumor necrosis
factor (TNF) receptor superfamily, is a soluble decoy re-
ceptor with a pleiotropic immunomodulatory effect via
“decoy” and “nondecoy” functions.6 In addition to
neutralizing the biological effects of Fas ligand, lympho-
toxin-like, exhibits inducible expression, and competes with
herpes simplex virus glycoprotein D for HVEM, a receptor
expressed by T lymphocytes (LIGHT), and TNF-like molecule
1A,7e9 DcR3 can promote M2 macrophage differentiation via
epigenetic regulation, after binding to syndecans and other
proteoglycans. Moreover, DcR3 promotes tumorigenesis
via the induction of tumor-associated macrophages.9e12
Accumulating evidence from in vitro and in vivo studies
also indicates that DcR3 can attenuate inflammatory
responses,13e16 which suggests that DcR3 is a pleiotropic
immunomodulator in negatively regulating inflammatory
responses. A previous study reported elevated levels of
DcR3 in the serum of atopic patients.17 However, only pa-
tients aged < 20 years were enrolled in that study, leaving
the question unanswered of whether serum DcR3 levels are
correlated with disease severity in adult asthma and non-
asthma patients. To address this question, we investigated
the associations between serum DcR3 levels and clinical
parameters of asthma such as laboratory variables, pulmo-
nary function test results, and disease severity.Patients and methods
Patients
The present study enrolled patients with asthma and
healthy controls (HCs) at Taipei Veterans General Hospital
(Taipei, Taiwan) and Cheng Hsin Rehabilitation Medical
Center (Taipei, Taiwan). All participants were aged >
20 years. All asthma patients had a history of asthma, and
the diagnosis was confirmed by evidence of reversibility of
airway obstruction [i.e., an increase >12% and 200 mL of
the initial forced expiratory volume in 1 second (FEV1)
with a short-acting bronchodilator or methacholine
sensitivity (PC20) < 8 mg/mL]. We also assessed the
atopic status of all patients with asthma. Atopy was
defined as the presence of IgE antibodies specific to at
least one common allergen such as house dust mites (e.g.,
Dermatophagoides pteronyssinus and Dermatophagoides
farinae), cat dander, dog dander, and cockroaches.18,19
The HCs had no history of, or findings consistent with
allergic disease. Patients and HCs with malignancy or
chronic inflammation disease were excluded. In addition,
study participants with signs and symptoms of infection
during the previous 2 weeks were excluded. The Asthma
Control Test (ACT) score (range, 5e25) was used to assess
asthma control.20 The ACT is a validated five-question
self-administered assessment tool in which higher scores
reflect better asthma control. This study was approved by
the institutional ethics committees of Taipei Veterans
General Hospital (Taipei, Taiwan) and Cheng Hsin Reha-
bilitation Medical Center (Taipei, Taiwan). Informed con-
sent was obtained from all patients participating in the
study.Laboratory assay and pulmonary function testing
Total serum IgE concentration and serum allergen-specific
IgE were measured using the ImmunoCAP system (Phar-
macia, Uppsala, Sweden). Blood eosinophils were counted
using a Coulter counter (Beckman Coulter, Inc., Fullerton,
CA, USA). Serum DcR3 levels were detected in triplicate
using an enzyme-linked immunosorbent assay (ELISA)
method (Human Soluble DcR3/TNFRSF6B ELISA Kit; Bio-
Legend, San Diego, CA, USA). For patients whose DcR3
level was below the detectable limit, the serum DcR3 level
was counted as 0 pg/mL. The average of triplicate results
for DcR3 was used in our analysis. The FEV1 and forced
vital capacity (FVC) were evaluated on the same day that
blood samples were collected. The predicted value of
DcR3 in nonatopic asthma patients 51pulmonary function test was adjusted for age, height, and
sex.
Statistical analysis
The mean DcR3 levels in the different groups were
compared using the ManneWhitney U test. Spearman cor-
relations were used to assess the associations between
DcR3 levels and clinical characteristics, laboratory results,
pulmonary function test results, and ACT scores. All p
values are two-tailed and were regarded as significant when
< 0.05. All statistical analyses were conducted using SPSS
software (SPSS 15.0 for Windows; SPSS, Chicago, IL, USA).
Results
Clinical characteristics of asthma patients and HCs
Seventy patients with asthma and 20 age- and sex-matched
HCs were enrolled (Table 1). The average age was
53.8 years (range, 21e80 years) for asthma patients and
51.3 years (range, 30e70 years) for HCs. Forty-three
(61.4%) asthma patients and 12 (60.0%) HCs were male.
Compared with the HCs, the asthma patients had higher
means for total eosinophil count and IgE level, and lower
mean predicted FEV1 and mean FEV1/FVC (for all,
p < 0.05). The mean  the standard deviation (SD) total
eosinophil count and mean  SD IgE level were
262.8  210.3 cells/uL and 351.6  740.9 KU/L, respec-
tively, in the asthma patients and 130.0  63.7 cells/uL and
39.3  38.1 KU/L, respectively, in the HCs. The percentages
of predicted FEV1 and FEV1/FVC were 81.4%  19.5% and
70.6%  14.3%, respectively, in the asthma patients and
96.2%  4.6% and 93.3%  3.1%, respectively, in the HCs.Table 1 Demographic and clinical characteristics of patients w
HCs
(n Z 20)
Asthm
(n Z 7
Age (y), mean (SD) 51.3 (9.9) 53.8 (1
Sex, male, n (%) 12 (60.0) 43 (61
Disease duration (y), median (range) d 25 (1e
Smoking, n (%) 2 (10.0) 12 (17
Laboratory profiles
Total eosinophil count (/mL), mean (SD) 130.0 (63.7) 262.8
Total IgE (KU/L), mean (SD) 39.3 (38.1) 351.6
Pulmonary function test
% of predicted FEV1, mean (SD) 96.2 (4.6) 81.4 (1
% of predicted FEV1/FVC, mean (SD) 93.3 (3.1) 70.6 (1
Antiasthmatic drugs
Bronchodilators, n (%) d 63 (90
Leukotriene antagonists, n (%) d 13 (18
Corticosteroids, n (%) d 14 (20
Asthma control test score, mean (SD) d 20.1 (4
FEV1 Z forced expiratory volume in 1 second; FVC Z forced vital ca
* Indicates a significant value, p < 0.05.
a Statistical comparison between asthma patients and HCs.
b Statistical comparison between atopic and nonatopic asthma patiThe mean ACT score in the asthma group was 20.1  4.0
(range, 7e25).
Differences in demographic and clinical
characteristics between patients with atopic and
nonatopic asthma
Table 1 shows the demographic, laboratory, and clinical
characteristics of the atopic and nonatopic asthma pa-
tients. Twenty-four (64.9%) of the 37 atopic asthma pa-
tients and 19 (57.6%) of the 33 nonatopic asthma patients
were male; the sex ratio did not differ significantly be-
tween the two groups (p Z 0.532). However, compared
with the nonatopic patients, patients with atopic asthma
were significantly younger (49.6  14.3 years vs.
58.6  12.6 years, pZ 0.005) and had a significantly longer
disease duration (21.3  17.5 years vs. 9.6  9.4 years,
p Z 0.005). The total IgE concentration was significantly
higher in the atopic patients than in the nonatopic patients
(535.0  967.6 IU/mL vs. 138.6  167.8 IU/mL, pZ 0.001);
however, the difference in the total eosinophil count be-
tween the two groups did not reach statistical significance
(270.6  192.6/mL vs. 254.4  231.1/mL, p Z 0.534). In
addition, there was no significant difference between these
subgroups in the percentages of predicted FEV1 and FEV1/
FVC or in the ACT scores (p Z 0.602, p Z 0.377, and
p Z 0.886, respectively).
Serum DcR3 levels in asthma patients and HCs
Decoy receptor 3 was detected in 52 (74.3%) of the 70
asthma patients and 7 (35.0%) of the 20 HCs. The mean  SD
serum DcR3 level in the asthma patients was
266.1  60.6 pg/mL, which was significantly higher than theith asthma and healthy controls.
a patients
0)
p a Asthma patients (n Z 70) p b
Atopic
(n Z 37)
Nonatopic
(n Z 33)
4.2) 0.434 49.6 (14.3) 58.6 (12.6) 0.005 *
.4) 0.908 24 (64.9) 19 (57.6) 0.532
59) d 19 (1e59) 6.5 (1e30) 0.005 *
.1) 0.727 4 (10.8) 8 (24.2) 0.135
(210.3) 0.022 * 270.6 (192.6) 254.4 (231.1) 0.534
(740.9) <0.001 * 535.0 (967.6) 138.6 (167.8) 0.001 *
9.5) <0.001 * 80.7 (21.0) 82.1 (18.1) 0.602
4.3) <0.001 * 68.8 (14.7) 72.6 (13.8) 0.377
.0) d 34 (91.9) 29 (87.9) 0.335
.6) d 7 (18.9) 6 (18.2) 0.937
.0) d 9 (24.3) 5 (15.2) 0.577
.0) d 20.0 (4.0) 20.2 (3.8) 0.886
pacity; HC Z healthy control; SD Z standard deviation.
ents.
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(63.7  21.9 pg/mL; p Z 0.003; Figure 1A). To assess the
importance of DcR3 elevation, we analyzed the association
of the DcR3 level with laboratory characteristics and dis-
ease activity. We found that the serum DcR3 level was
inversely correlated with the percentages of predicted
FEV1 and FEV1/FVC (r Z 0.276, p Z 0.024 and
r Z 0.311, p Z 0.003, respectively). However, there was
no significant association of DcR3 level with the total
eosinophil count, total IgE concentration, or ACT score
(r Z 0.120, p Z 0.375; r Z 0.226, p Z 0.068; and
r Z 0.223, p Z 0.079, respectively).
Serum DcR3 levels in atopic and nonatopic asthma
patients and correlation with disease activity
To determine the importance of DcR3 elevation in atopic
and nonatopic asthma patients, we analyzed the associa-
tion of DcR3 level with laboratory characteristics and dis-
ease activity in these subgroups. The mean DcR3 level was
higher in the 37 atopic patients than in the 33 nonatopicFigure 1 Serum decoy receptor 3 (DcR3) levels are signifi-
cantly higher in asthma patients than in age- and sex-matched
healthy controls. (A) The serum DcR3 levels measured in 70
asthma patients and 20 healthy controls enrolled in the study.
(B) The analysis of data from 37 patients with atopic asthma
and 33 patients with nonatopic asthma. For each participant,
the DcR3 level was detected by enzyme-linked immunosorbent
assay (ELISA), in accordance with the manufacturer’s in-
structions. * Indicates a significant difference (p < 0.05).asthma patients, but the difference was not statistically
significant (298.7  111.2 pg/mL vs. 230.6  38.5 pg/mL,
p Z 0.064; Figure 1B).
In nonatopic patients, we found that the serum DcR3
level was positively correlated with the total eosinophil
count (r Z 0.448, p Z 0.012; Figure 2A) and inversely
correlated with the percentages of predicted FEV1 and
FEV1/FVC, and ACT score (r Z 0.409, p Z 0.018,
r Z 0.399, p Z 0.021, and r Z 0.505, p Z 0.003,
respectively; Figures 2C, 2E, and 2G). There was no corre-
lation between the serum DcR3 level and serum total IgE
concentration (rZ 0.065, pZ 0.728). By contrast, among
the atopic asthma patients, the serum DcR3 levels were not
correlated with the aforementioned variables such as the
total eosinophil count (Figure 2B), total IgE concentration,
percentages of predicted FEV1 (Figure 2D) and FEV1/FVC
(Figure 2F), or ACT score (Figure 2H) (rZ 0.003, pZ 0.988;
rZ 0.270, pZ 0.117; rZ 0.211, pZ 0.231; rZ 0.047,
p Z 0.791; and r Z 0.141, p Z 0.428, respectively).
Five nonatopic asthma patients had a follow-up assess-
ment. For each patient, an ACT score was recorded and the
serum DcR3 level was measured at each clinic visit. Asthma
exacerbations were observed in Patients A, C, and E, and
their serum DcR3 levels were increased (Figures 3A, 3C, and
3E). Their serum DcR3 levels decreased when their asthma
status improved. By contrast, the asthma status of Patients
B and D was under control and no significant changes were
noted in their serum DcR3 level (Figures 3B and 3D). These
longitudinal observations suggested that DcR3 levels can
serve as a good biomarker for asthma severity.Discussion
In this study, we found that the serum DcR3 levels were
significantly higher in adult asthma patients than in age-
and sex-matched HCs. In addition, serum DcR3 levels were
inversely correlated with disease activity in adult patients
with nonatopic asthma only, which suggests that DcR3
levels could serve as a biomarker for predicting disease
severity in the future. DcR3 downregulates inflammatory
reactions by secreting anti-inflammatory cytokines and
decreasing the production of proinflammatory cytokines.6
Our findings also implied the potential role of DcR3 in
nonatopic asthma.
Previous investigators have reported elevated serum
DcR3 levels in pediatric asthma patients. One study of
children with asthma and healthy children found signifi-
cantly higher serum DcR3 levels in asthmatic children
aged 5e10 years.17 However, DcR3 levels have not previ-
ously been evaluated in adults with asthma. In the pre-
sent study, the serum DcR3 levels were significantly
higher in asthma patients aged > 20 years than in HCs.
This observation suggests that DcR3 may have an impor-
tant role in asthma.
Atopic asthma is triggered by an allergen-induced Th2
response, which is correlated with eosinophilia and increased
serum IgE levels1,2; however, the causes of nonatopic asthma
development are unclear and reliable markers for disease
severity are absent. A previous study demonstrated that DcR3
is upregulated in various disease states such as autoimmune
disorders, infectious diseases, and cancer.6 Thus, DcR3
Figure 2 Serum decoy receptor 3 (DcR3) level is positively correlated with disease severity in nonatopic asthma patients.
Spearman correlation coefficients of serum DcR3 levels in (A, C, E, G) nonatopic asthma patients and (B, D, F, H) atopic asthma
patients and disease activity. (A, B) Comparison between the DcR3 serum concentrations and serum total eosinophil count; (C, D)
percentage of predicted FEV1, (E, F), percentage of predicted FEV1/FVC; and (G, H) Asthma Control Test (ACT) score (range,
5e25). * Indicates significant correlation (p < 0.05). FEV1 Z forced expiratory volume in 1 second; FVC Z forced vital capacity.
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Figure 3 The serum decoy receptor 3 (DcR3) level reflects asthma severity in individual patients with nonatopic asthma. There
are longitudinal changes in the serum DcR3 levels and asthma control in five patients with nonatopic asthma. For each patient, the
Asthma Control Test (ACT) score was recorded and the serum DcR3 level was measured at each clinic visit. Asthma exacerbations
occurred in Patients A, C, and E, and their serum DcR3 levels were increased. Their serum DcR3 levels decreased when their asthma
status improved. By contrast, the asthma status of Patients B and D is under control and their serum DcR3 level has no significant
changes.
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actions triggered by various antigens, and is not limited to
atopic reactions only. The significant correlation between
serum DcR3 levels and disease severity in nonatopic asthma
patients may reflect multiple factors involved in triggering
inflammatory reactions, which may lead to the upregulation
of DcR3 and attenuate clinical symptoms in nonasthma
patients.
Patients with asthma frequently have high blood eosin-
ophilia. Eosinophil accumulation in the asthmatic lung leads
to tissue injury and bronchial inflammation, and is associ-
ated with airway remodeling.21,22 Marked elevation of
blood eosinophil counts may reflect severe asthma activity
and has been used to predict acute exacerbations.23e25Spirometry is a method that objectively assesses pul-
monary function and is important for evaluating current
asthma severity. The FEV1 values and FEV1/FVC ratios are
used to assess airway obstruction and usually decrease
during asthma attacks. The ACT questionnaire is the
simplest of the relevant instruments and is widely used to
evaluate asthma control.26 In this study, we found that
the serum DcR3 level was positively correlated with total
eosinophil count, and inversely correlated with other
important indicators of disease activity in patients with
nonatopic asthma, which suggests that it may be used as a
biomarker of disease severity in this subgroup.
DcR3 may act as a negative regulator of immune re-
sponses. In a previous study,6 DcR3 was proven to
DcR3 in nonatopic asthma patients 55attenuate inflammation by neutralizing TNF-like molecule
1A, LIGHT, and Fas ligand. In addition, DcR3 drives mac-
rophages toward the M2 phenotype, which has an anti-
inflammatory property characterized by the secretion of
anti-inflammatory cytokines and the decreased produc-
tion of proinflammatory cytokines.14 Another study
showed that DcR3 can block LIGHT-lymphotoxin-ß
receptor-mediated signaling, which activates dendritic
cells and induces a cytotoxic T cell response.27 Further-
more, by using CD68 promoter-driven DcR3 transgenic (Tg)
mice, we have proven that DcR3-Tg mice displayed higher
levels of interleukin (IL)-10, IL-1ra, Ym1, and arginase
activity, whereas the expression of IL-12, TNF-a, IL-6,
nitric oxide, and major histocompatibility complex class
II was downregulated.12 Higher serum DcR3 levels were
associated with higher disease severity in our nonatopic
asthma patients. It is possible that DcR3 can be main-
tained at high levels to downregulate inflammatory re-
actions. However, how DcR3 is upregulated and how it
regulates airway inflammation remains unknown. Recent
studies have shown that the expression of DcR3 is stimu-
lated by lipopolysaccharides or TNF-a.28,29 In addition, it
has been determined that NF-kB activation is essential for
DcR3 expression.30 However, no evidence has been re-
ported that indicates that any medicine can mediate the
expression of DcR3. In this study, patients with asthma
received treatment with oral corticosteroids, leukotriene
receptor antagonists, sustained-release theophylline, or
inhaled corticosteroids plus inhaled b2-agonist.
Based on the follow-up results of the five nonatopic
asthma patients, we found that serum DcR3 levels were
correlated with disease severity, which implies that the
treatment effect may influence the DcR3 levels. However,
there was no difference in serum DcR3 levels among our
asthma patients with similar disease activity who received
different treatment regimens. Whether specific anti-
asthmatic drugs can influence serum levels of DcR3 directly
is unknown and further studies are needed. We failed to
demonstrate a correlation between serum DcR3 levels and
disease severity in the atopic asthma subgroup. It is well
documented that allergen-specific IgE antibodies, mast
cells, Th2 cells, and Th2 cytokines are responsible for the
development of atopic asthma, which suggests that DcR3
only partially contributes to the pathogenesis of this disease.
In conclusion, this is the first study to report elevated
serum DcR3 levels in adult asthma patients. In addition,
high serum DcR3 levels were associated with severe disease
activity in nonatopic asthma. Because of the fact that
serum markers were correlated with disease severity in
nonatopic asthma patients has not previously been re-
ported, it is possible that DcR3 levels may serve as a
biomarker in these patients.
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